News

Patients treated with ocrelizumab had a 6.2% risk of progressing to wheelchair use compared to people taking placebo who had a 9.8% risk.

The FDA has approved moxidectin 8 mg oral for the treatment of onchocerciasis (river blindness) in patients aged 12 years and older.

Researchers found that patients with depression were at increased risk of cognitive decline long before dementia could be diagnosed.

The CDC reports that of the 2 million people who get an infection from antibiotic-resistant bacteria each year, about 23,000 die.

The FDA granted Fast Track designation to REGENXBIO Inc for its product, RGX-111, a novel, single-dose investigational treatment for mucopolysaccharidosis type 1.

The FDA has approved bevacizumab for patients with ovarian, fallopian tube, or primary peritoneal cancer in combination with carboplatin and paclitaxel, followed by single-agent bevacizumab, for either stage 3 or 4 disease after initial surgical resection.

The FDA has approved pembrolizumab for the treatment of refractory primary mediastinal large B-cell lymphoma (PMBCL) or who have relapsed after 2 or more previous lines of therapy.

The first patient has been dosed in Actinium Pharmaceuticals’ phase 1 trial evaluating Actimab-A in combination with CLAG-M for patients with relapsed or refractory (r/r) acute myeloid leukemia (AML).

The survey revealed that 89% of practitioners said that their patients use screens for fewer than 10 hours each day, despite 33% of adults reporting passing that mark.

The FDA Circulatory System Devices Panel of the Medical Devices Advisory Committee panel voted 11-4 to support the benefits of the INCRAFT AAA Stent Graft System from Cardinal Health.

Children with conditions such as ADHD could be put at greater risk of obesity or type 2 diabetes due to antipsychotic prescriptions.

At 29th of 195 countries, the US in the 9th decile along with countries including the UK, Malta, Lebanon, Singapore, and South Korea.

The FDA has approved methoxy polyethylene glycol-epoetin beta (Mircera) for the treatment of anemia associated with chronic kidney disease in pediatric patients aged 5 to 17 years of age on dialysis.

Most patients, whether or not they had preoperative fluid, saw improved BCVA post-surgery, and there were no significant differences in central subfield thickness.

Misconceptions linger, and they’re not helping anyone.

A University of Surrey research professor has developed a mathematical model based on earlier models, for monitoring HCV progression and treatment response.

The FDA grants rare pediatric disease designation to Albiero Pharma Inc.’s A4250 for the treatment of PFIC, a rare liver disease for which no approved treatment is currently available.

e FDA grants Fast Track designation to 177Lu-lilotomab satetraxetan (Betalutin) for the treatment of patients with relapsed/refractory follicular lymphoma after at least 2 prior systemic therapies.

The timing of administrating the drug didn’t seem to matter in terms of efficacy.

The catheter is now indicated for use with an aspiration technique for blood clot removal in patients with acute ischemic stroke.

Thus far, MindMotion GO has been trialed with upward of 300 patients, with early findings suggesting the amplification of both patient engagement and adherence to therapy.

The therapy's currently-planned phase 3 trials for major depressive disorder, postpartum depression disorder are being converted into pivotal studies after a meeting with the FDA.

The FDA has granted orphan drug designation to GPLSCD01 for the treatment of limbal stem cell deficiency.

This is the first study to demonstrate that prescription drugs were often used concurrently, and that polypharmacy was associated with a greater likelihood of experiencing depression.

The wearable device, Drug Relief, is a non-narcotic option for treatment and eases withdrawal symptoms within just 30-60 minutes.

Dimerix shares update on DMX-200, a combination therapy of propagermanium and irbesartan for the treatment of focal segmental sclerosis in addition to chronic kidney disease.

An amphetamine salts mixture (SHP465) showed efficacy in improving problem solving and sustaining attention in ADHD adults.

Montefiore has made it a point to seek to improve the health of its patients in the classroom, the doctor’s office, and the community itself.

AIMS scores can vary based on the clinician and therefore action plans may differ.

The oral treatment was safe and efficacious over the course of a 12-week treatment period.